Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM

Award Number: R44DK117714
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM - Project Summary Acute Kidney Injury (AKI) is common in hospitalized patients after severe illness or following major surgeries, such as cardiovascular surgery. The incidence of AKI in critically ill patients is greater than 40%. Patients who have an AKI event have poor long-term outcomes including increased debilitating comorbidities such as chronic kidney disease and increased mortality. Ischemia/reperfusion injury (IRI), an unavoidable consequence of cardiovascular surgery, is a known cause of AKI. IRI is partially the result of the formation of reactive oxygen species (ROS) in the absence of sufficient antioxidative moieties, and can lead to the induction of inflammation. There is currently no clinically available therapeutic treatment to prevent or treat AKI, which leaves a large cohort of suffering patients and a high burden on our healthcare system. Our product, APP-103™, consists of effective anti-oxidant and anti-inflammatory copolymer nanoparticles that have previously been demonstrated to be highly effective in ameliorating damage from oxidative stress in several IRI models of kidney, heart, limb injury, and renal transplantation. APP-103™ is a dispersion of polyoxalate-vanillyl alcohol (VA) copolymer particles that is degraded by hydrogen peroxide, thereby reducing the local concentration of ROS and yielding anti-inflammatory VA. The polymer chemistry and biology of APP-103 is well understood and indicative of an excellent safety profile. While easily administered systemically, it offers site-specific anti-oxidative and anti-inflammatory therapy without expensive and marginally effective targeting molecules. A single 500 nm diameter APP™ particle provides the ability to mitigate ~1011 ROS molecules, and is activated only in the presence of ROS, i.e. APP activity is self-limiting. To date, we have been able to produce APP-103™ at the scale necessary for preclinical work, and are advancing through IND-enabling studies with no toxicity. We have also demonstrated efficacy in pre-clinical AKI models. The purpose of this proposal is to provide mechanistic insight of APP-103 in kidney IRI, demonstrate proof of concept in a large animal model of AKI, and then advance APP-103™ from lab manufacturing through completion of IND-enabling studies. The milestone of ultimate success will be the submission of an IND in order to bring this exceptionally promising therapy into clinical application.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	9/8/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $747,225 )
2021	2021	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	3	7/20/2021	NON-COMPETING CONTINUATION	$747,225
2021	2020	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	3/2/2021	EXTENSION WITH OR WITHOUT FUNDS	$0
2021	2020	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	11/5/2020	EXTENSION WITH OR WITHOUT FUNDS	$0
2021	2019	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	1	3/11/2021	NEW	$0
														Subtotal = $747,225

Issue Date FY: 2020 ( Subtotal = $998,624 )
2020	2020	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	7/24/2020	EXTENSION WITH OR WITHOUT FUNDS	$998,624
2020	2019	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/7/2020	NEW	$0
														Subtotal = $998,624

Issue Date FY: 2019 ( Subtotal = $224,170 )
2019	2019	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/22/2019	NEW	$224,170
														Subtotal = $224,170

Grand Total All Awards = $1,970,019

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM

Award Number: R44DK117714

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer